GHSG HD16试验的随访:早期预后良好霍奇金淋巴瘤中PET指导的治疗
GHSG HD16试验长期随访报告:1150例18-75岁新诊断早期预后良好霍奇金淋巴瘤患者随机接受标准联合模式治疗(CMT)或PET-2指导的治疗(PET-2阴性时省略放疗)。中位随访64个月,PET-2阴性患者5年无进展生存率CMT组94.2% vs 单纯ABVD组86.7%(HR=2.05,p=0.0072),5年总生存率两组分别为98.3%和98.8%(p=0.14)。结论认为无论PET-2结果如何,CMT应被视为早期预后良好霍奇金淋巴瘤的标准治疗。
要点
- PET-2阴性患者5年PFS:CMT组94.2% vs 单纯ABVD组86.7%(HR=2.05,p=0.0072)。
- 5年OS两组分别为98.3%和98.8%(p=0.14),12例记录死亡中4例为第二原发恶性肿瘤,仅1例死于霍奇金淋巴瘤。
- CMT组中PET-2阴性患者5年PFS优于阳性患者(94.0% vs 90.3%,p=0.012),以DS4为界差异更明显(94.0% vs 83.6%,p<0.0001)。
核心结论
- 无论PET-2结果如何,CMT应被视为早期预后良好霍奇金淋巴瘤的标准治疗。
研究设计与样本
- GHSG HD16试验的长期随访分析,纳入1150例18-75岁新诊断早期预后良好霍奇金淋巴瘤患者。
- 患者随机接受标准联合模式治疗(CMT:2周期ABVD后行PET/CT[PET-2]及20 Gy累及野放疗)或PET-2指导的治疗(PET-2阴性即Deauville评分[DS]<3时省略放疗)。
- 研究旨在排除PET-2指导治疗的劣效性,并评估PET-2在接受CMT患者中的预后影响。
主要发现
- 中位随访64个月,PET-2阴性患者5年无进展生存率CMT组为94.2%(n=328),单纯ABVD组为86.7%(n=300;HR=2.05 [1.20-3.51];p=0.0072)。
- 5年总生存率两组分别为98.3%和98.8%(p=0.14);12例记录死亡中4例由第二原发恶性肿瘤导致,仅1例由霍奇金淋巴瘤导致。
- 在分配至CMT的患者中,PET-2阴性患者(n=353;94.0%)5年PFS优于PET-2阳性患者(n=340;90.3%;p=0.012)。
- 以DS4为界时差异更明显:DS 1-3组(n=571)5年PFS为94.0%,DS≥4组(n=122)为83.6%(p<0.0001)。
临床怎么用
- 作者结论认为,无论PET-2结果如何,CMT应被视为早期预后良好霍奇金淋巴瘤的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (n = 328) and 86.7% after ABVD alone (n = 300; HR = 2.05 [1.20-3.51]; p = 0.0072). 5-year OS was 98.3% and 98.8%, respectively (p = 0.14); 4/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (n = 353; 94.0%) than in PET-2-positive patients (n = 340; 90.3%; p = 0.012). The difference was more pronounced when using DS4 as cut-off (DS 1-3: n = 571; 94.0% vs. DS ≥ 4: n = 122; 83.6%; p < 0.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result.
引用
- Fuchs M, Jacob AS, Kaul H, et al. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia. 2023. PMID: 37845285. doi:10.1038/s41375-023-02064-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。